Protection of human immunodeficiency virus type 2-exposed seronegative macaques from mucosal simian immunodeficiency virus transmission.
about
Host background immunity and human immunodeficiency virus protective vaccines, a major consideration for vaccine efficacy in Africa and in developing countries.Protection of macaques against intrarectal infection by a combination immunization regimen with recombinant simian immunodeficiency virus SIVmne gp160 vaccinesFactors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251.Occult systemic infection and persistent simian immunodeficiency virus (SIV)-specific CD4(+)-T-cell proliferative responses in rhesus macaques that were transiently viremic after intravaginal inoculation of SIVHighly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation.CD8+ lymphocytes do not mediate protection against acute superinfection 20 days after vaccination with a live attenuated simian immunodeficiency virusBoth mucosal and systemic routes of immunization with the live, attenuated NYVAC/simian immunodeficiency virus SIV(gpe) recombinant vaccine result in gag-specific CD8(+) T-cell responses in mucosal tissues of macaques.Prevention of human immunodeficiency virus and AIDS: postexposure prophylaxis (including health care workers)Chronic immune activation associated with chronic helminthic and human immunodeficiency virus infections: role of hyporesponsiveness and anergyCytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi.The importance of local mucosal HIV-specific CD8(+) cytotoxic T lymphocytes for resistance to mucosal viral transmission in mice and enhancement of resistance by local administration of IL-12.Human immunodeficiency virus (HIV)-2-specific T lymphocyte proliferative responses in HIV-2-infected and in HIV-2-exposed but uninfected individuals in Guinea-Bissau.
P2860
Q24531918-BC36E2AE-03B0-402E-B26D-2961BD0F0E70Q33644522-34F2782C-9574-490F-BB2E-56A1F6735494Q33649657-386C55D9-896A-4E87-8B79-6A3FB3CA12C1Q33786143-A600E9A8-39AE-4E85-8DA5-E3BB6DEF4495Q33814150-483D9DDA-83F7-484D-8E86-3CA47FB087FCQ33984208-E0B633E6-84D3-46BA-92DF-742119EB5F47Q34355037-3A5FC5F6-1EDD-4631-BC9B-F810506EF606Q34619859-37F88736-E996-464F-9440-C4910E5189F0Q35920663-39F740E3-3CE7-46CD-BB8F-025EB0EB26A1Q37387851-E62BF3FE-AE03-4DE0-B8F9-CCEB9949101CQ37388157-48F6C0C1-41F4-46D8-897F-9B6EE5C8C15AQ43825794-E8696FAE-244C-405A-84A7-4C59BBC91AE4
P2860
Protection of human immunodeficiency virus type 2-exposed seronegative macaques from mucosal simian immunodeficiency virus transmission.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Protection of human immunodefi ...... deficiency virus transmission.
@ast
Protection of human immunodefi ...... deficiency virus transmission.
@en
type
label
Protection of human immunodefi ...... deficiency virus transmission.
@ast
Protection of human immunodefi ...... deficiency virus transmission.
@en
prefLabel
Protection of human immunodefi ...... deficiency virus transmission.
@ast
Protection of human immunodefi ...... deficiency virus transmission.
@en
P2093
P2860
P1433
P1476
Protection of human immunodefi ...... odeficiency virus transmission
@en
P2093
Biberfeld G
Böttiger D
Mäkitalo B
Putkonen P
Thorstensson R
P2860
P304
P407
P577
1997-07-01T00:00:00Z